Bright Minds Biosciences Inc. (DRUG)
Automate Your Wheel Strategy on DRUG
With Tiblio's Option Bot, you can configure your own wheel strategy including DRUG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DRUG
- Rev/Share 0.0
- Book/Share 11.4464
- PB 15.1773
- Debt/Equity 0.0021
- CurrentRatio 36.1012
- ROIC -0.1302
- MktCap 971317836.6358
- FreeCF/Share -1.1627
- PFCF -116.5482
- PE -80.7124
- Debt/Assets 0.0015
- DivYield 0
- ROE -0.1975
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DRUG | BTIG Research | -- | Buy | -- | $72 | Sept. 8, 2025 |
| Initiation | DRUG | TD Cowen | -- | Buy | -- | -- | May 13, 2025 |
| Initiation | DRUG | Chardan Capital Markets | -- | Buy | -- | $80 | May 7, 2025 |
| Initiation | DRUG | Piper Sandler | -- | Overweight | -- | $93 | Jan. 23, 2025 |
| Initiation | DRUG | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 10, 2025 |
| Initiation | DRUG | H.C. Wainwright | -- | Buy | -- | $85 | Jan. 10, 2025 |
News
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by …
Read More
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101.
Read More
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials
Published: December 15, 2025 by: Proactive Investors
Sentiment: Positive
For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer's disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy. But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are reviving interest in the field.
Read More
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.
Read More
About Bright Minds Biosciences Inc. (DRUG)
- IPO Date 2021-03-22
- Website https://brightmindsbio.com
- Industry Biotechnology
- CEO Ian McDonald
- Employees None